{"filings":[{"id":2217036,"accession_number":"0001835268-26-000027","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2026-08-12T20:13:33+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma Q2 net loss $17.3M; enrollment done in both Seabreeze STAT trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2026 net loss $17.3M ($0.27/share) vs $12.9M ($0.23) in Q2 2025; H1 loss $36.7M ($0.61).","Cash, equivalents, short-term investments $31.5M at June 30, 2026; runway at least one year.","Enrollment completed in Phase 2 Seabreeze STAT asthma (160 pts) and COPD (159 pts) studies; topline results expected September 2026.","Initiated open-label Phase 2 Seabreeze STAT IV trial (40 participants) evaluating IV rademikibart for acute exacerbations.","Simcere license revenue $2.8M in Q2 (vs $48K prior year); eligible for up to ~$99M in remaining milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":23281,"accession_number":"0001835268-26-000019","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2026-05-12T13:02:24+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma reports Q1 net loss $19.4M; Phase 2 studies on track, topline data mid-2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $19.4M ($0.34 loss per share) vs $10.3M loss ($0.19 per share) in Q1 2025.","Cash $46.0M as of March 31, 2026; expects funding into H2 2027.","Phase 2 Seabreeze STAT asthma/COPD studies continuing after DMC review; topline data expected mid-2026.","Completed $20.2M private placement led by Panacea Venture on March 31, 2026.","R&D expense $15.0M (up from $6.6M) due to rademikibart development; license revenue $0.2M from Simcere agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":169000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96027,"accession_number":"0001835268-26-000016","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Connect Biopharma: DMC Recommends Continue Phase 2 Asthma/COPD Trials; Topline Data Mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DMC reviewed pre-specified interim efficacy of rademikibart (anti-IL-4Rα) in Phase 2 Seabreeze STAT trials; no sample size change.","No treatment-related serious adverse events, no severe AEs, and no discontinuations due to AEs in either study.","Topline data from both asthma and COPD studies expected in mid-2026; company plans FDA meeting for Phase 3.","CEO Barry Quart: 'Rademikibart has potential to deliver differentiated efficacy and safety in acute exacerbations.'"],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109525,"accession_number":"0001835268-26-000012","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma FY2025 net loss $55.5M; cash runway extended by $20.2M placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2025 $55.5M ($1.00 per share) vs $15.6M ($0.28 per share) in FY2024.","Cash and equivalents $44.3M at Dec 31, 2025; with private placement net proceeds, runway into H2 2027.","Private placement raised $20.2M gross from 6.13M shares at $3.25 each; closed March 31, 2026.","Phase 1 IV rademikibart showed rapid FEV1 improvement in asthma/COPD; Phase 2 Seabreeze STAT topline data expected mid-2026.","R&D expense increased to $37.8M (FY2025) from $29.3M due to Phase 2 study initiation."],"consensus_eps_estimate":-1.22,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":169000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109524,"accession_number":"0001835268-26-000006","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"Connect Biopharma private placement $20.2M; Phase 1 IV rademikibart shows rapid bronchodilation; Phase 3 AD efficacy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Raised $20.2M via private placement of 6.13M shares at $3.25; led by Panacea Venture; extends cash runway into H2 2027.","Phase 1 IV rademikibart: rapid FEV1 improvements of 200-400 mL within 15 mins in asthma/COPD, maintained through Day 29.","Phase 3 AD study: 96.6% EASI-75, 87.1% IGA 0/1, 85.3% EASI-90 at week 52; safety comparable to placebo, low conjunctivitis.","Phase 2 Seabreeze STAT data for acute exacerbations expected mid-2026; plans to meet FDA for Phase 3 alignment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126047,"accession_number":"0001835268-25-000061","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-12-23T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Connect Biopharma board member Kan Chen resigns amid U.S.-centric shift","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kan Chen, Ph.D., partner at Qiming Venture Partners, resigned from Board and Nominating Committee effective Dec 17, 2025.","Resignation not due to any disagreement with company on operations, policies or practices.","Chen cited company's successful strategic shift to become more U.S.-centric as appropriate time to step down."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126046,"accession_number":"0001835268-25-000057","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma Q3 net loss $17.2M; cash $54.8M; Seabreeze STAT studies on track for 1H26 topline","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $17.2M ($0.31 per share) in Q3 2025 vs $12.9M ($0.23) in Q3 2024; 9-month net loss $40.4M ($0.73) vs $6.7M ($0.12).","License revenue dropped to $16K (Q3) and $64K (9M) from $1.2M and $25.3M in prior-year periods due to upfront and milestone recognition in 2024.","R&D expense increased to $11.1M (Q3) from $9.0M, reflecting initiation of Phase 2 Seabreeze STAT asthma/COPD studies.","Simcere NDA for rademikibart in atopic dermatitis accepted by China NMPA; Connect eligible for up to ~$110M in milestones plus tiered royalties.","Phase 2 Seabreeze STAT studies recruiting participants; topline data expected 1H2026. Cash position of $54.8M expected to fund operations into 2027."],"consensus_eps_estimate":-1.014,"consensus_eps_actual":-0.73,"consensus_revenue_estimate":null,"consensus_revenue_actual":64000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142774,"accession_number":"0001835268-25-000056","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-09-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Connect Biopharma CEO and President buy 439,773 shares over past 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CEO Barry Quart purchased 224,034 shares from Sep 2024 to Sep 2025.","President David Szekeres purchased 215,739 shares from Nov 2024 to Sep 2025.","All purchases were made in compliance with the Company's Insider Trading Compliance Policy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142773,"accession_number":"0001835268-25-000051","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma Q2 net loss $12.9M; cash $71.8M; ADR program termination planned","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.9M ($0.23) vs net income $14.8M ($0.27) in Q2 2024; revenue $48K vs $24.1M.","Cash $71.8M expected to fund operations into 2027; R&D $8.8M up from $5.3M on Phase 2 trials.","Phase 2 Seabreeze STAT asthma/COPD studies recruiting; topline data expected H1 2026.","Simcere submitted NDA in China for rademikibart (AD); Connect eligible for up to $110M milestones.","Plans to terminate ADR program by Sep 2, 2025; ordinary shares to list on Nasdaq under CNTB."],"consensus_eps_estimate":-0.9192,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":48000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142772,"accession_number":"0001835268-25-000047","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Connect Biopharma appoints James A. Schoeneck to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board size increased from six to seven; Schoeneck appointed effective July 22, 2025.","Schoeneck is former CEO of Depomed (2011-2017) and BrainCells (2005-2011).","Currently serves as independent director and chairman at FibroGen and Calidi Biotherapeutics.","Board determined Schoeneck is independent under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142771,"accession_number":"0001835268-25-000044","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"Connect Biopharma terminates ADR program; ordinary shares to list directly on Nasdaq under CNTB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On July 18, 2025, ordered termination of Deposit Agreement with Deutsche Bank Trust Company Americas.","ADR program and Deposit Agreement expected to terminate on or about September 2, 2025.","Each ADS (1 ordinary share) will be mandatorily cancelled and exchanged for ordinary shares 1:1.","Company plans to list ordinary shares directly on Nasdaq under symbol CNTB after ADR termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142770,"accession_number":"0001835268-25-000039","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Connect Biopharma regains Nasdaq minimum bid price compliance; delisting risk removed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on July 17, 2025 confirming compliance with Minimum Bid Price Requirement.","Regained compliance after ADSs closed at or above $1.00 for 10 consecutive business days through July 15, 2025.","Non-compliance was first notified on March 24, 2025; cure period ran to September 22, 2025.","Matter is now closed; no further action required to maintain listing.","Removal of delisting risk supports continued trading on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142769,"accession_number":"0001628280-25-034551","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Connect licensee Simcere submits NDA for rademikibart in China for atopic dermatitis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Simcere submitted NDA to NMPA for rademikibart to treat atopic dermatitis in adults and adolescents.","Connect eligible for up to $110M in remaining development, regulatory, and commercial milestone payments.","Connect also eligible for tiered royalties up to low double-digit percentages on Greater China net sales.","Rademikibart is a next-generation IL-4Rα antibody; AD market in China estimated at 70M patients.","Connect retains all rights outside Greater China under the 2023 license agreement with Simcere."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160860,"accession_number":"0001835268-25-000033","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma Q1 net loss $10.3M; cash $84M; initiates two Phase 2 rademikibart trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and ST investments $84.0M as of March 31, 2025; runway into 2027.","Net loss $10.3M ($0.19/share) vs $8.7M ($0.16) in Q1 2024; R&D expense $6.6M, down $2.1M YoY.","Initiated Phase 2 Seabreeze STAT asthma and COPD studies for rademikibart; topline data expected 1H 2026.","Phase 2 data published in AJRCCM showed 420 mL FEV1 improvement vs placebo in eosinophilic asthma."],"consensus_eps_estimate":-1.9245,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160859,"accession_number":"0001835268-25-000029","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Connect Biopharma starts Phase 2 COPD study of rademikibart, topline data expected 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 Seabreeze STAT COPD study initiated after FDA agreement on final protocol.","Study evaluates single-dose rademikibart vs placebo as adjunct to standard of care for acute COPD exacerbations.","Approximately 160 participants with type 2 inflammation (eosinophils ≥300 cells/μL) will be enrolled.","Primary endpoint: treatment failure rate over 28 days; topline data expected in first half of 2026.","Post-hoc analysis of prior Phase 2b asthma data in COPD-like patients to be presented at ATS 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160858,"accession_number":"0001835268-25-000026","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Connect Biopharma initiates Phase 2 Seabreeze STAT study of rademikibart for acute asthma exacerbations","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2 Seabreeze STAT Asthma study (NCT06940141) initiated after FDA agreement on final protocol.","Evaluates rademikibart as adjunct to standard of care in ~160 adults/adolescents with type 2 inflammation asthma.","Primary endpoint: treatment failure rate over 28 days; secondary include exacerbations and lung function.","Topline data expected in first half of 2026.","Imminently on track to initiate a similarly-designed Phase 2 study in COPD."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160857,"accession_number":"0001835268-25-000019","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Connect Biopharma gains FDA alignment for Phase 2 trials of rademikibart in acute asthma/COPD","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA Type C meeting positive; agency aligned on parallel Phase 2 trials for rademikibart in acute exacerbations of asthma or COPD.","Two placebo-controlled trials each enrolling ~160 patients with eosinophils ≥300 cells/µL; single 600 mg SC dose over 28 days.","Initiation planned in Q2 2025; data expected in first half of 2026; cash runway into 2027.","CEO cites prior Phase 2 maintenance data showing rapid lung function improvement within 24 hours of 600 mg dose.","Unmet need highlighted: ~45% of patients on standard of care experience treatment failure within 28 days post-exacerbation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179052,"accession_number":"0001835268-25-000013","cik":1835268,"company_name":"Connect Biopharma Holdings Ltd","ticker":"CNTB","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Connect Biopharma reports FY2024 net loss $15.6M; cash $93.7M into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $26.0M from Simcere license; no revenue in FY2023.","R&D expense $29.3M (-$23.7M YoY) as Phase 2b asthma/atopic dermatitis trials completed.","Net loss $15.6M ($0.28 EPS) vs $62.1M ($1.13) in FY2023.","Phase 2 trials of rademikibart for acute asthma/COPD start Q2 2025; data expected H2 2026.","CEO Barry Quart leads U.S.-centric shift; HQ relocated to San Diego, transition to domestic filer."],"consensus_eps_estimate":-1.9245,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":154576263.00208333,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}